Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ziopharm Oncology has received notice from the European Patent Office that it intends to grant a patent with claims covering certain pharmaceutical formulations of indibulin for oral administration and processes for manufacturing such formulations.
Subscribe to our email newsletter
The company also received a notice from the US Patent and Trademark Office that it intends to grant a patent with claims covering certain methods for treating multidrug-resistant tumors or inhibiting metastasis with various pharmaceutical compounds, including indibulin.
Indibulin is an oral novel tubulin targeted agent. The drug is currently being evaluated in several Phase I and Phase I/II studies, both as a single agent and in combination with Tarceva and Xeloda, for the treatment of a variety of solid tumors.
Jonathan Lewis, CEO and chief medical officer of Ziopharm, said: “These patent notices of allowance extend our already substantial intellectual property portfolio for indibulin.”